These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 18971124)

  • 1. Acromegaly, growth hormone and cancer risk.
    Renehan AG; Brennan BM
    Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):639-57. PubMed ID: 18971124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does growth hormone cause cancer?
    Jenkins PJ; Mukherjee A; Shalet SM
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):115-21. PubMed ID: 16430706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications.
    Renehan AG; O'Connell J; O'Halloran D; Shanahan F; Potten CS; O'Dwyer ST; Shalet SM
    Horm Metab Res; 2003; 35(11-12):712-25. PubMed ID: 14710350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversies in the risk of neoplasia in GH deficiency.
    Pekic S; Stojanovic M; Popovic V
    Best Pract Res Clin Endocrinol Metab; 2017 Feb; 31(1):35-47. PubMed ID: 28477731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the GH-IGF axis play a role in cancer pathogenesis?
    Cohen P; Clemmons DR; Rosenfeld RG
    Growth Horm IGF Res; 2000 Dec; 10(6):297-305. PubMed ID: 11161960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The GH-IGF-I axis and the cardiovascular system: clinical implications.
    Colao A
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):347-58. PubMed ID: 18462260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The critical parameters in GH excess.
    Sheppard MC
    J Endocrinol Invest; 2005; 28(5 Suppl):92-5. PubMed ID: 16114283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of differentiated thyroid carcinoma in acromegaly.
    Tita P; Ambrosio MR; Scollo C; Carta A; Gangemi P; Bondanelli M; Vigneri R; degli Uberti EC; Pezzino V
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):161-7. PubMed ID: 16060909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acromegaly induced by growth hormone replacement therapy.
    Karges B; Pfäffle R; Boehm BO; Karges W
    Horm Res; 2004; 61(4):165-9. PubMed ID: 14707471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice.
    Bielohuby M; Roemmler J; Manolopoulou J; Johnsen I; Sawitzky M; Schopohl J; Reincke M; Wolf E; Hoeflich A; Bidlingmaier M
    Exp Biol Med (Maywood); 2009 Aug; 234(8):1002-9. PubMed ID: 19491373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy for the syndromes of GH excess.
    Arosio M; Cannavò S; Epaminonda P; Ronchi C; Chiodini I; Adda G
    J Endocrinol Invest; 2003; 26(10 Suppl):36-43. PubMed ID: 15497658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess.
    Wiesli P; Zwimpfer C; Zapf J; Schmid C
    Acta Obstet Gynecol Scand; 2006; 85(8):900-5. PubMed ID: 16862465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic tests and basal values for defining active acromegaly.
    Tzanela M
    Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acromegaly and cancer.
    Jenkins PJ
    Horm Res; 2004; 62 Suppl 1():108-15. PubMed ID: 15761242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neoplastic complications of acromegaly.
    Terzolo M; Daffara F; Reimondo G; Allasino B; Ventura M; Angeli A
    J Endocrinol Invest; 2003; 26(8 Suppl):32-4. PubMed ID: 15233209
    [No Abstract]   [Full Text] [Related]  

  • 19. Cancers associated with acromegaly.
    Jenkins PJ
    Neuroendocrinology; 2006; 83(3-4):218-23. PubMed ID: 17047386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocysteine levels in acromegaly patients.
    Hekimsoy Z; Ozmen B; Ulusoy S
    Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.